Hari Menon1, Roshal R Patel2, Taylor R Cushman1, Arya Amini3, Steven N Seyedin4, Anngela C Adams1, Chi Lin5, Vivek Verma6. 1. Department of Radiation Oncology, University of Arizona College of Medicine - Phoenix, Phoenix, AZ 85004, USA. 2. Department of Radiation Oncology, Albany Medical College, Albany, NY 12208, USA. 3. Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA. 4. Department of Radiation Oncology, University of Iowa Hospital & Clinics, Iowa City, IA 52242, USA. 5. Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA. 6. Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA.
Abstract
Aims: To analyze outcomes in primary anorectal melanoma, a rare disease with limited data and treatment guidelines. Materials & methods: We analyzed 305 subjects in the National Cancer Database from 2004 to 2015. The primary end point was overall survival (OS). Results: Surgery was predictive of OS (median 2.24 vs 1.18 years; p = 0.009) with no survival difference between local and transabdominal approaches (p = 0.77). No OS benefit was seen with chemotherapy (p = 0.16), radiotherapy (p = 0.31) or adjuvant therapy post surgery (p > 0.05 for all groups). Targeted therapy trended toward higher survival in metastatic patients (1.33 vs 0.55 years; p = 0.06). Conclusion: In nonmetastatic patients, surgery of any method is associated with a survival benefit. The trend for improved survival following targeted therapy in metastatic patients merits further exploration.
Aims: To analyze outcomes in primary anorectal melanoma, a rare disease with limited data and treatment guidelines. Materials & methods: We analyzed 305 subjects in the National Cancer Database from 2004 to 2015. The primary end point was overall survival (OS). Results: Surgery was predictive of OS (median 2.24 vs 1.18 years; p = 0.009) with no survival difference between local and transabdominal approaches (p = 0.77). No OS benefit was seen with chemotherapy (p = 0.16), radiotherapy (p = 0.31) or adjuvant therapy post surgery (p > 0.05 for all groups). Targeted therapy trended toward higher survival in metastatic patients (1.33 vs 0.55 years; p = 0.06). Conclusion: In nonmetastatic patients, surgery of any method is associated with a survival benefit. The trend for improved survival following targeted therapy in metastatic patients merits further exploration.
Authors: Esther Jutten; Schelto Kruijff; Anne Brecht Francken; Martijn F Lutke Holzik; Barbara L van Leeuwen; Henderik L van Westreenen; Kevin P Wevers Journal: BJS Open Date: 2021-11-09